Find a Clinical Trial

Showing 1 - 9 out of 9

Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus

2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized,
Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the
Efficacy and Safety of BIIB059 in Participants with Active Subacute
Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus
Erythematosus with or without Systemic Manifestations and Refractory
and/or Intolerant to Antimalarial Therapy (AMETHYST)

Cutaneous disorders

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Gemini 1

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio^®) in participants with relapsing forms of multiple sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Hercules

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

Multiple sclerosis

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PERSEUS

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Atopic Dermatitis (Eczema)

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Atopic dermatitis

All genders

12-17

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

NRAD

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.

Alzheimer's disease, Mild cognitive impairment

All genders

55-89

Recruiting now

Department of Psychiatry

Tufts Medical Center

Learn more

Remodel-2

Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

THC-AD

Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (AD) (THC-AD)

Alzheimer's disease, Psychiatric disorders

All genders

60-95

Recruiting now

Department of Psychiatry

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio^®) in participants with relapsing forms of multiple sclerosis

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.

Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis

Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s disease (AD) (THC-AD)